Rift In Eli Lilly-Cadila Alliance? Partners Mum But R&D Deal May Have Been Called Off
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly and India’s Cadila break up what was to be a six-year CV discovery alliance.
You may also be interested in...
Lilly Shifts Gears In China With New Shanghai-based R&D Center
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
After 10-year Partnership, Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center In Asia
MUMBAI - Bristol-Myers Squibb and Syngene - Biocon's contract research services arm - cemented a 10-year long association with the opening of what is called Asia's largest research facility near Bangalore. Syngene was established in 1994 and was the first to offer contract research services out of India. Syngene has now grown to become Biocon's fastest growing arm and has research alliances with Novartis and Merck